Notably, PI3K/mTOR signaling to Akt is a key oncogenic pathway driving tumor cell survival and treatment resistance (8, 9), and aberrant PI3K/mTOR pathway mutations are found in 50% of cases of residual disease (RD) in TNBCs following neoadjuvant chemotherapy (NAC; ref. 10). Here, AKT1 is linked to neoplasm.